US-based Catalyst Biosciences raised $13.4m in funding in September as part of a planned $18.6m round, according to a filing with the Securities and Exchange Commission.
Catalyst is backed by US-based healthcare company Johnson & Johnson Development Corporation and return backers Sofinnova Ventures, Burrill & Company, Morgenthaler Ventures, HealthCare Ventures, and Essex Woodlands Health Ventures.
Catalyst Biosciences is a developer of next generation biopharmaceuticals that target proteins underlying diseases.
This latest round of funds brings the total raised by the drug company to $83.4m after raising $30m in Series B funding in 2006 and $40m in Series C funding.